Patil Armenian, Benjamin Hatten
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Drs. Summergrad and Insel reflect on the progress and remaining questions in psychedelic science since 2017. They delve into topics like efficacy, regulation, therapy, and provider experience.
Paul Summergrad, Tom Insel, Rachel Nuwer
Dr. Dölen presents evidence linking psychedelics to reopening the social reward learning critical period, suggesting a shared mechanism across these drugs. This metaplastic restoration of oxytocin-mediated long-term depression may have
Elliot Cohen (Pillpack, Amazon) and Protik Basu (World Bank, UN, Helena) share insights on healthcare delivery, psychedelics industry, scaling challenges, and technology's role in patient care.
Andrew “Mo” Septimus, Protik Basu, Elliot Cohen
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Stanislav Grof, a pioneer in psychedelic research, presents the Grof® Legacy Training on 'holotropic' states of consciousness, with colleagues from international psychedelic training programs.
Brigitte Grof, Stanislav Grof, Diane Haug, Javier Charme, Neil Hannon, Jay Dufrechou
Carl Hart, Chair of Psychology at Columbia University, is a renowned neuropsychopharmacologist, author, and media personality known for challenging drug perceptions through research, books, and media appearances.
Carl Hart
NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study
Joshua A Gordon
Hardman provides a quick overview of the emerging psychedelic sector, covering financial, research, and policy landscapes with data visuals. He also explores unanswered questions about the sector's future.
Josh Hardman
Discussion between experts on pragmatic frameworks, demographic considerations, and evidence-based practices shaping psychedelic policy reform for diverse contexts, addressing regulatory challenges and fostering nuanced understanding.
Tatiana Quintana, Melissa Lavasani, Logan Davidson